142 related articles for article (PubMed ID: 37545048)
1. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
Carrabba NV; Siliezar PD; Laylani N; Lee AG
Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
[No Abstract] [Full Text] [Related]
2. [Subretinal fluid associated with MEK and BRAF inhibitors].
Attia R; Comet A; Stolowy N; Fitoussi R; Michel T; Denis D; David T
J Fr Ophtalmol; 2022 Nov; 45(9):1091-1092. PubMed ID: 35908992
[No Abstract] [Full Text] [Related]
3. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
Demarez B; Eté M; David L; Quiles N; Archier E
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
[No Abstract] [Full Text] [Related]
4. Panniculitis in patients treated with BRAF/MEK inhibitors: Presentation of 4 new cases.
Cordeiro González P; Taibo Martínez A; Peña Penabad C
Med Clin (Barc); 2022 Jun; 158(11):e8-e9. PubMed ID: 34996624
[No Abstract] [Full Text] [Related]
5. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
6. BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval.
Mullard A
Nat Rev Drug Discov; 2022 Aug; 21(8):548. PubMed ID: 35794466
[No Abstract] [Full Text] [Related]
7. What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?
Rutkowski P; Rogala P
Expert Opin Pharmacother; 2023; 24(10):1101-1103. PubMed ID: 37144819
[No Abstract] [Full Text] [Related]
8. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
[TBL] [Abstract][Full Text] [Related]
9. Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
Le Goubey JB; Sassier M; Nakouri I; De Pontville M; Césaire L; Aide N; Kottler D
Melanoma Res; 2023 Apr; 33(2):159-161. PubMed ID: 36815470
[No Abstract] [Full Text] [Related]
10. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
[TBL] [Abstract][Full Text] [Related]
11. Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.
Bormann JL; Kerkvliet AM
Cutis; 2023 Sep; 112(3):E17-E20. PubMed ID: 37903392
[No Abstract] [Full Text] [Related]
12. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.
Marani A; Gioacchini H; Paolinelli M; Offidani A; Campanati A
Expert Opin Drug Metab Toxicol; 2023; 19(8):555-567. PubMed ID: 37659065
[TBL] [Abstract][Full Text] [Related]
13. Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
Buchacher L; Richtig G; Dernoscheg M; Richtig E; Koch L
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e605-e607. PubMed ID: 36645848
[No Abstract] [Full Text] [Related]
14. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B
Melanoma Res; 2022 Jun; 32(3):183-191. PubMed ID: 35377866
[TBL] [Abstract][Full Text] [Related]
15. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract][Full Text] [Related]
16. Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.
De Ryck L; Delanghe S; Jacobs C; Fadaei S; Brochez L; Saerens M
Acta Clin Belg; 2023 Jun; 78(3):215-222. PubMed ID: 35996969
[TBL] [Abstract][Full Text] [Related]
17. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
19. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
20. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
